Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study
Brief Summary: This study was conducted to assess the safety, immunogenicity, efficacy and long-term effectiveness of a vaccine being evaluated for the prevention of human papillomavirus (HPV) infection and disease in mid-adult women.


Options:
A: Arm Label: HPV-16/18 Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV 16/18 L1 AS04 | Arm Label: HPV-TETRA A Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 1 | Arm Label: HPV-TETRA B Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 2 | Arm Label: HPV-TETRA C Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 3 | Arm Label: HPV-TETRA D Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 4 | Arm Label: HPV-TETRA E Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 5 | Arm Label: HPV-TETRA F Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18/31/45 L1 AS04 Formulation 6 | Intervention Type: BIOLOGICAL; Name: HPV 16/18 L1 AS04; Assigned to Arm(s): HPV-16/18 Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 1; Assigned to Arm(s): HPV-TETRA A Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 2; Assigned to Arm(s): HPV-TETRA B Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 3; Assigned to Arm(s): HPV-TETRA C Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 4; Assigned to Arm(s): HPV-TETRA D Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 5; Assigned to Arm(s): HPV-TETRA E Group | Intervention Type: BIOLOGICAL; Name: HPV-16/18/31/45 L1 AS04 Formulation 6; Assigned to Arm(s): HPV-TETRA F Group
B: Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1/AS04; Assigned to Arm(s): N/A
C: Arm Label: 12 months; Type: EXPERIMENTAL; Interventions: Biological: quadrivalent human papillomavirus vaccine | Arm Label: 6 month; Type: ACTIVE_COMPARATOR; Interventions: Biological: quadrivalent human papillomavirus vaccine | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 12 months | Intervention Type: BIOLOGICAL; Name: quadrivalent human papillomavirus vaccine; Assigned to Arm(s): 6 month
D: Arm Label: qHPV Vaccine in Base Study; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Arm Label: Placebo in Base Study; Type: PLACEBO_COMPARATOR; Interventions: Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine; Assigned to Arm(s): Placebo in Base Study, qHPV Vaccine in Base Study | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): Placebo in Base Study

Answer: D